Top

Published in:

01-02-2009 | Case Report

A case report of a patient with refractory adult-onset Still’s disease who was successfully treated with tocilizumab over 6 years

Authors: Hideko Nakahara, Toru Mima, Naoko Yoshio-Hoshino, Masato Matsushita, Jun Hashimoto, Norihiro Nishimoto

Published in: Modern Rheumatology | Issue 1/2009

Abstract

Interleukin-6 overproduction is pathologically involved in adult onset Still’s disease (AOSD). We successfully treated a man with refractory AOSD utilizing tocilizumab. Tocilizumab was discontinued after 15 doses due to intestinal bleeding, but the efficacy was sustained over 21 months. Tocilizumab was readministered safely upon recurrence and showed similar efficacy over 6 years. Corticosteroid and NSAIDs could be discontinued and intestinal bleeding was no more observed. Tocilizumab can be a therapeutic option for AOSD.

Bywaters EGL. Still’s disease in the adult. Ann Rheum Dis. 1971;30:121–33.PubMedCrossRef

Yamaguchi M, Ohta A, Tsunematsu T, Kasukawa R, Mizushima Y, Kashiwagi H, et al. Preliminary criteria for classification of adult Still’s disease. J Rheumatol. 1992;29:424–30.

Chen DY, Lan JL, Lin FJ, Hsieh TY. Proinflammatory cytokine profiles in sera and pathological tissues of patients with active untreated adult onset Still’s disease. J Rheumatol. 2004;31:2189–98.PubMed

Scheinberg MA, Chapira E, Fernandes ML, Hubscher O. Interleukin 6: a possible marker of disease activity in adult onset Still’s disease. Clin Exp Rheumatol 1992; 653–5.

Nishimoto N, Kishimoto T, Yoshizaki K. Anti-interleukin 6 receptor antibody treatment in rheumatoid arthritis. Ann Rheum Dis. 2000;59(suppl 1):i21–7.PubMedCrossRef

Sato K, Tsuchiya M, Saldanha J, Koishihara Y, Ohsugi Y, Kishimoto T, et al. Reshaping a human antibody to inhibit the interleukin-6-dependent tumor cell growth. Cancer Res. 1993;53:851–6.PubMed

Yokota S, Miyamae T, Imagawa T, Iwata N, Katakura S, Mori M, et al. Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2005;52:818–25.PubMedCrossRef

Woo P, Wilkinson N, Prieur AM, Southwood T, Leone V, Livermore P, et al. Open-label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement. Arthritis Res Ther. 2005;7:R1281–8.PubMedCrossRef

Yokota S, Imagawa T, Mori M, Miyamae T, Aihara Y, Takei S, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomized, double-blind, placebo-controlled, withdrawal phase III trial. Lancet. 2008;371:998–1006.PubMedCrossRef

10.

Iwamoto M, Nara H, Hirata D, Minota S, Nishimoto N, Yoshizaki K. Humanized monoclonal anti-interleukin 6 receptor antibody for treatment of intractable adult-onset Still’s disease. Arthritis Rheum. 2002;46:3388–9.PubMedCrossRef

11.

Nishimoto N, Hashimoto J, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomized controlled trial of tocilizumab. Ann Rheum Dis. 2007;66:1162–7.PubMedCrossRef

12.

Information for proper use of infliximab (in Japanese) by Tanabe Seiyaku. http://medical.tanabe.co.jp/mstaff/remicade/index_remicade.shtml.

13.

Saiki O, Uda H, Nshimoto N, Miwa T, Mima T, Ogawara T, et al. Adult Still’s disease reflects a Th2 rather than a Th1 cytokine profile. Clin Immunol. 2004;112:120–5.PubMedCrossRef

14.

Olee T, Hashimoto S, Quach J, Lotz M. IL-18 is produced by articular chondrocytes and induces proinflammatory and catabolic responses. J Immunol. 1999;162:1096–100.PubMed

15.

Jablonska E, Jablonski J. Effect of IL-18 on the release of IL-6 and its soluble receptors: sIL-6Rα and sgp 130 by human neutrophils. Immunological Investigations. 2002;31:159–67.PubMedCrossRef

16.

Yamamura M, Kawashima M, Taniai M, Yamauchi H, Tanimoto T, Kurimoto M, et al. Interferon-γ-inducing activity of interleukin-18 in the joint with rheumatoid arthritis. Arthritis Rheum. 2001;44:275–85.PubMedCrossRef

Title: A case report of a patient with refractory adult-onset Still’s disease who was successfully treated with tocilizumab over 6 years
Authors: Hideko Nakahara
Toru Mima
Naoko Yoshio-Hoshino
Masato Matsushita
Jun Hashimoto
Norihiro Nishimoto
Publication date: 01-02-2009
Publisher: Springer Japan
Published in: Modern Rheumatology / Issue 1/2009
Print ISSN: 1439-7595
Electronic ISSN: 1439-7609
DOI: https://doi.org/10.1007/s10165-008-0116-2

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

A case report of a patient with refractory adult-onset Still’s disease who was successfully treated with tocilizumab over 6 years

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2009

Sjogren’s syndrome: promising, new treatment options besides nizatidine

Hyper-IgD syndrome with novel mutation in a Japanese girl

Cyclosporin A treatment for Japanese patients with severe adult-onset Still’s disease

A case of immunoglobulin G4-related chronic sclerosing sialadenitis and dacryoadenitis associated with tuberculosis

Masked early symptoms of pneumonia in patients with rheumatoid arthritis during tocilizumab treatment: a report of two cases

Disease activity and the course of wrist joint deterioration over 10 years in the patients with early rheumatoid arthritis

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page